RL95-2Homo sapiens (Human)Cancer cell line

Also known as: RL95, RL952, RL-952, RL-95-2, RL95_2

🤖 AI SummaryBased on 12 publications

Quick Overview

Human endometrial adenocarcinoma cell line for cancer research.

Detailed Summary

RL95-2 is a human endometrial adenocarcinoma cell line established from a Grade 2 moderately differentiated adenosquamous carcinoma of the endometrium. It has been passaged in culture for over 2 years and exhibits epithelioid morphology with well-defined junctional complexes, tonofilaments, and microvilli. The cell line shows a log phase doubling time of 22-34 hours and forms gland-like structures. It is used in studies related to endocrine regulation, chemosensitivity, and radiosensitivity. RL95-2 has been utilized in research on platinum-based chemotherapy sensitivity and sublethal damage repair after fractionated irradiation. The cell line is also characterized by the presence of estrogen receptors and has been employed in investigations of tumor biology and therapeutic responses.

Research Applications

Chemosensitivity testingRadiosensitivity analysisEndocrine regulation studiesTumor biology investigationTherapeutic response evaluation

Key Characteristics

Epithelioid morphologyEstrogen receptor positiveModerately differentiatedForm gland-like structuresSublethal damage repair capacity

Generated on 6/15/2025

Basic Information

Database ID	CVCL_0505
Species	Homo sapiens (Human)
Tissue Source	Endometrium[UBERON:UBERON_0001295]

Donor Information

Age	65
Age Category	Adult
Sex	Female
Race	caucasian

Disease Information

Disease	Endometrial adenosquamous carcinoma
Lineage	Uterus
Subtype	Uterine Adenosquamous Carcinoma
OncoTree Code	UASC

DepMap Information

Source Type	ATCC
Source ID	ACH-000965_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Val218del (c.646_648GTG[2]) (c.652_654delGTG)	Homozygous	-	PubMed=31541927
MutationSimple	TP53	p.Val73Trpfs*50 (c.216delC) (p.P72fs)	Heterozygous	-	Unknown, Unknown, PubMed=9887230
MutationSimple	PTEN	p.Asn323Metfs*21 (c.968delA)	Heterozygous	-	PubMed=20944090
MutationSimple	PTEN	p.Asn323fs*2 (c.968_969insA)	Heterozygous	-	from parent cell line SK-UT-1
MutationSimple	KMT2D	p.Arg1252Ter (c.3754C>T)	Heterozygous	-	from parent cell line 22Rv1
MutationSimple	HRAS	p.Gln61His (c.183G>T)	Heterozygous	-	Unknown, Unknown, Unknown
MutationSimple	ARID1A	p.Arg693Ter (c.2077C>T)	Heterozygous	-	Unknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

CSF1PO

10,11

D10S1248

14,15

D12S391

15,21

D13S317

8,12

D16S539

11,13

D18S51

10,14

D19S433

D1S1656

13,19.3

D21S11

28,29

D22S1045

D2S1338

22,23

D2S441

11,14

D3S1358

14,16

D5S818

10,11

D7S820

D8S1179

10,14

FGA

20,22

Penta D

Penta E

5,11

TH01

9,9.3

TPOX

vWA

16,20

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOI PubMed PMC

Genomic characterization of five commonly used endometrial cancer cell lines.

Devor E.J., Gonzalez-Bosquet J., Thiel K.W., Leslie K.K.

Int. J. Oncol. 57:1348-1357(2020).

DOI PubMed PMC

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

DOI PubMed PMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOI PubMed PMC

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

DOI PubMed

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOI PubMed PMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOI PubMed PMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOI PubMed PMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOI PubMed

DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.

Lessey B.A., Jordan V.C., Bradford A.P.

Gynecol. Oncol. 127:241-248(2012).

DOI PubMed PMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOI PubMed PMC

PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.

Lord C.J., Ashworth A., Reis-Filho J.S.

Sci. Transl. Med. 2:53ra75.1-53ra75.8(2010).

DOI PubMed

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOI PubMed PMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOI PubMed PMC

Three-dimensional coculture of endometrial cancer cells and fibroblasts in human placenta derived collagen sponges and expression matrix metalloproteinases in these cells.

Tanaka R., Saito T., Ashihara K., Nishimura M., Mizumoto H., Kudo R.

Gynecol. Oncol. 90:297-304(2003).

DOI PubMed

p53 mutations and presence of HPV DNA do not correlate with radiosensitivity of gynecological cancer cell lines.

Syrjanen S.M.

Gynecol. Oncol. 71:352-358(1998).

DOI PubMed

Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines.

Rantanen V., Grenman S.E., Kulmala J., Grenman R.

Br. J. Cancer 69:482-486(1994).

DOI PubMed PMC

Sublethal damage repair after fractionated irradiation in endometrial cancer cell lines tested with the 96-well plate clonogenic assay.

Grenman R.

J. Cancer Res. Clin. Oncol. 120:712-716(1994).

DOI PubMed

Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture.

Way D.L., Grosso D.S., Davis J.R., Surwit E.A., Christian C.D.

In Vitro 19:147-158(1983).

DOI PubMed

Characteristics of cell lines derived from normal and malignant endometrial tissue.

Noumoff J.S., Haydock S.W., Sachdeva R., Heyner S., Pritchard M.L.

Gynecol. Oncol. 27:141-149(1987).

DOI PubMed

Radiation sensitivity of endometrial carcinoma in vitro.";

Rantanen V., Grenman S.E., Kulmala J., Salmi T., Grenman R.

Gynecol. Oncol. 44:217-222(1992).

DOI PubMed

Web Resources

tcpaportal.org